cryoprecipitaattiyksikkö

Cryoprecipitate is a blood product derived from fresh frozen plasma. It is obtained by thawing plasma at a controlled, low temperature and then collecting the insoluble precipitate that forms. This precipitate is rich in certain plasma proteins, including fibrinogen, von Willebrand factor, and Factor VIII. These components are crucial for blood clotting.

Cryoprecipitate is used clinically to treat bleeding disorders caused by deficiencies of these specific clotting factors. For instance, it is the primary treatment for hemophilia A (Factor VIII deficiency) and von Willebrand disease. It is also used to manage disseminated intravascular coagulation (DIC), a serious condition where widespread clotting consumes clotting factors. In surgical settings, cryoprecipitate may be administered to control excessive bleeding.

The preparation of cryoprecipitate requires careful temperature control during thawing to maximize the yield of the desired proteins. It is typically administered intravenously. While generally safe, like all blood products, it carries a risk of transfusion reactions, including allergic reactions and the transmission of infectious diseases, although screening protocols have significantly reduced these risks. The decision to administer cryoprecipitate is made by a healthcare professional based on the patient's clinical condition and laboratory test results.